Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

NATALY APOLLONSKY

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1730309246
CMS profile
811234
Location
PHILADELPHIA, PA

General Payments · PY2018–2024

$56,750.34

  • Reported across 45 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$19,698.81

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $17,672.00 2
Travel and Lodging $1,499.98 6
Food and Beverage $468.25 4
Education $58.58 1

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $19,613.60 10
VERTEX PHARMACEUTICALS INCORPORATED $58.58 1
Agios Pharmaceuticals, Inc. $17.39 1
Novo Nordisk AS $9.24 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $175.03 3
PY2019 $10,774.21 9
PY2020 $2,100.00 1
PY2021 $8,669.85 8
PY2022 $8,215.65 7
PY2023 $7,116.79 4
PY2024 $19,698.81 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Agios Pharmaceuticals, Inc. $17.39 07/23/2024 Travel and Lodging Undisputed 01/23/2026 1149643734 CMS
GENZYME CORPORATION $15.78 09/26/2024 Food and Beverage Undisputed 01/23/2026 1139654895 CMS
GENZYME CORPORATION $157.86 10/05/2024 Food and Beverage Undisputed 01/23/2026 1139654901 CMS
GENZYME CORPORATION $181.66 10/05/2024 Travel and Lodging Undisputed 01/23/2026 1139654903 CMS
GENZYME CORPORATION $152.93 10/05/2024 Travel and Lodging Undisputed 01/23/2026 1139654905 CMS
GENZYME CORPORATION $7,896.00 10/05/2024 Consulting Fee Undisputed 01/23/2026 1139654907 CMS
GENZYME CORPORATION $285.37 11/02/2024 Food and Beverage Undisputed 01/23/2026 1139654909 CMS
GENZYME CORPORATION $306.66 11/02/2024 Travel and Lodging Undisputed 01/23/2026 1139654911 CMS
GENZYME CORPORATION $701.34 11/02/2024 Travel and Lodging Undisputed 01/23/2026 1139654913 CMS
GENZYME CORPORATION $140.00 11/02/2024 Travel and Lodging Undisputed 01/23/2026 1139654915 CMS
GENZYME CORPORATION $9,776.00 11/02/2024 Consulting Fee Undisputed 01/23/2026 1139654917 CMS
Novo Nordisk Inc $9.24 05/16/2024 Food and Beverage Undisputed 01/23/2026 1097327208 CMS
VERTEX PHARMACEUTICALS INCORPORATED $58.58 07/18/2024 Education Undisputed 01/23/2026 1105916086 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.